supported by the Natural Science Foundation of Shandong Province(No.ZR2020MH39)。
Objective:Ginsenoside Rh1(G-Rh1)has been confirmed to inhibit the growth of breast cancer and colon cancer,but its therapeutic effect on hepatocellular carcinoma(HCC)is unclear.This study investigates the therapeutic ...
supported by the grant from the Yangzhou Key Laboratory of Basic and Clinical Transformation of Digestive and Metabolic Diseases(No.YZ2020159).
Gastric cancer(GC)is a common gastrointestinal system malignancy.PACSIN1 functions as an oncogene in various cancers.This study aims to investigate the potential of PACSIN1 as a target in GC treatment.Gene expression ...
financially supported by the National Natural Science Foundation of China(32371457,32171374 and 32130058);Shandong Laboratory Program(SYS202205,China).
Current cytotoxic T lymphocyte(CTL)activating immunotherapy requires a major histocompatibility complex I(MHC-I)-mediated presentation of tumor-associated antigens,which malfunctions in around half of patients with tr...
The authors acknowledge the Natural Science Foundation of Shanghai(nos.20511101900,20ZR1427200,and 20ZR1425400).
Major histocompatibility complex class I(MHC-I),a key element of the acquired immune system,plays essential roles in activating CD8^(+)T cells by recognizing intracellular antigens derived from pathogens and cancer.As...
This work was supported by the National Natural Science Foundation of China,Nos.81671240(to SZZ),81560220(to GHL);the Youth Science Foundation of Jiangxi Province of China,No.20151BAB215014(to GHL);Health and Family Planning Commission of Jiangxi Province of China,No.20195109(to GHL)。
The expression of major histocompatibility complex class I(MHC-I),a key antigen-presenting protein,can be induced in dopaminergic neurons in the substantia nigra,thus indicating its possible involvement in the occurre...
Susan G.Komen Career Catalyst Grant CCR14299052(Balko JM),NIH/NCI SPORE 2P50CA098131-17(Balko JM),Department of Defense Era of Hope Award BC170037(Balko JM);the Vanderbilt-Ingram Cancer Center Support Grant P30 CA68485.Additional funding was provided by NIH T32GM007347(Axelrod ML)NIH T32CA009582-31(James JL)and F30CA236157(Axelrod ML).
Aim:Immunotherapy and immune checkpoint inhibitors(ICI)have changed cancer care for many patients;however,breast cancers have exhibited minimal response to single agent ICI therapy.There is a significant need to ident...